Patent classifications
C07D473/38
2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN
Compounds, pharmaceutical compositions, and methods are provided herein that may be used to treat cancer, infectious disease, and other conditions associated with ectonucleotide pyrophosphatase pyrophosphatase-phosphodiesterase (ENPP1) dysfunction.
THIOPURINE-BASED COMPOUND, COMPOSITION, METHOD OF PREPARATION AND APPLICATIONS
A compound for measurement of thiopurine pathway directed systems imaging and therapy including a chelator and a thiopurine ligand is provided. A method of synthesizing the compound is also provided, and the compound may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.
THIOPURINE-BASED COMPOUND, COMPOSITION, METHOD OF PREPARATION AND APPLICATIONS
A compound for measurement of thiopurine pathway directed systems imaging and therapy including a chelator and a thiopurine ligand is provided. A method of synthesizing the compound is also provided, and the compound may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.
METFORMIN DERIVATIVES
The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.
Purine inhibitors of human phosphatidylinositol 3-kinase delta
- Abdelghani Abe Achab ,
- Michael D. Altman ,
- Yongqi Deng ,
- Timothy Guzi ,
- Solomon Kattar ,
- Jason D. Katz ,
- Joey L. Methot ,
- Hua Zhou ,
- Meredeth McGowan ,
- Matthew P. Christopher ,
- Yudith Garcia ,
- Neville John Anthony ,
- Francesc Xavier Fradera Llinas ,
- Kin Chiu Fong ,
- Xiansheng Leng ,
- Changwei Mu ,
- Sixing Zhang ,
- Rong Zhang
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. ##STR00001##
Purine inhibitors of human phosphatidylinositol 3-kinase delta
- Abdelghani Abe Achab ,
- Michael D. Altman ,
- Yongqi Deng ,
- Timothy Guzi ,
- Solomon Kattar ,
- Jason D. Katz ,
- Joey L. Methot ,
- Hua Zhou ,
- Meredeth McGowan ,
- Matthew P. Christopher ,
- Yudith Garcia ,
- Neville John Anthony ,
- Francesc Xavier Fradera Llinas ,
- Kin Chiu Fong ,
- Xiansheng Leng ,
- Changwei Mu ,
- Sixing Zhang ,
- Rong Zhang
The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. ##STR00001##
PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF
The invention relates to prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.
PARP INHIBITORS FOR TREATING CANCER AND ASTHMA
Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.
PARP INHIBITORS FOR TREATING CANCER AND ASTHMA
Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.